{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:26:18Z","timestamp":1790331978825,"version":"4.1.0"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"45","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,8]]},"DOI":"10.18632\/oncotarget.12304","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T18:48:11Z","timestamp":1475088491000},"page":"73257-73269","source":"Crossref","is-referenced-by-count":65,"title":["An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Shuyao","family":"Tang","sequence":"first","affiliation":[{"name":"The Hepatosplenic Surgery Center, Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Hepatosplenic Surgery Center, Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Han","sequence":"additional","affiliation":[{"name":"The Hepatosplenic Surgery Center, Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Dong","sequence":"additional","affiliation":[{"name":"The Hepatosplenic Surgery Center, Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiquan","family":"Qiao","sequence":"additional","affiliation":[{"name":"The Hepatosplenic Surgery Center, Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchi","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Hepatosplenic Surgery Center, Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Sun","sequence":"additional","affiliation":[{"name":"The Hepatosplenic Surgery Center, Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Liang","year":"2009","journal-title":"Lancet Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Zeuzem","year":"2008","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","article-title":"Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design","volume":"20","author":"Hernandez-Gea","year":"2014","journal-title":"Clin Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1517\/13543784.2015.1058776","article-title":"Novel drugs in clinical development for hepatocellular carcinoma","volume":"24","author":"Trojan","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","article-title":"MicroRNAs in cancer","volume":"9","author":"Croce","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2741\/4358","article-title":"Role of microRNAs in hepatocellular carcinoma","volume":"20","author":"Zhang","year":"2015","journal-title":"Front Biosci (Landmark Ed)"},{"key":"8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2007.05.022","article-title":"MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer","volume":"133","author":"Patel","year":"2007","journal-title":"Gastroenterology"},{"key":"9","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/sj.onc.1210083","article-title":"miR-21-mediated tumor growth","volume":"26","author":"Mo","year":"2007","journal-title":"Oncogene"},{"key":"10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/14728222.2013.819853","article-title":"MicroRNA-21: a therapeutic target for reversing drug resistance in cancer","volume":"17","author":"Fan","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"11","doi-asserted-by":"publisher","first-page":"28867","DOI":"10.18632\/oncotarget.4814","article-title":"MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN\/Akt pathway","volume":"6","author":"Sun","year":"2015","journal-title":"Oncotarget"},{"key":"12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/1568009615666150225122635","article-title":"MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells","volume":"15","author":"Yang","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.26369","article-title":"MicroRNA-216a\/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer","volume":"58","author":"Hui","year":"2013","journal-title":"Hepatology"},{"key":"14","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3892\/ijo.2014.2577","article-title":"miR222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma","volume":"45","author":"Liu","year":"2014","journal-title":"Int J Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/or.2015.4030","article-title":"miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN","volume":"34","author":"Liu","year":"2015","journal-title":"Oncol Rep"},{"key":"16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nm.3981","article-title":"The emerging role of lncRNAs in cancer","volume":"21","author":"Huarte","year":"2015","journal-title":"Nat Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canlet.2015.02.035","article-title":"The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma","volume":"360","author":"Yang","year":"2015","journal-title":"Cancer Lett"},{"key":"18","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jmedgenet-2015-103334","article-title":"ceRNA in cancer: possible functions and clinical implications","volume":"52","author":"Ma","year":"2015","journal-title":"J Med Genet"},{"key":"19","doi-asserted-by":"publisher","first-page":"17805","DOI":"10.18632\/oncotarget.7525","article-title":"Role and mechanism of miR-222 in arsenic-transformed cells for inducing tumor growth","volume":"7","author":"He","year":"2016","journal-title":"Oncotarget"},{"key":"20","doi-asserted-by":"publisher","first-page":"30239","DOI":"10.18632\/oncotarget.4972","article-title":"MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN","volume":"6","author":"Yao","year":"2015","journal-title":"Oncotarget"},{"key":"21","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-13-1043","article-title":"Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma","volume":"13","author":"Sun","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"22","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1038\/onc.2012.567","article-title":"The evolution of the TOR pathway and its role in cancer","volume":"32","author":"Platanias","year":"2013","journal-title":"Oncogene"},{"key":"23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2016.02.008","article-title":"Personalized therapy for hepatocellular carcinoma: Where are we now?","volume":"45","author":"Chan","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"24","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/1535-7163.MCT-16-0096","article-title":"An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma","volume":"15","author":"Su","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"25","doi-asserted-by":"publisher","first-page":"49143","DOI":"10.18632\/oncotarget.9237","article-title":"Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Croce","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature09284","article-title":"OncomiR addiction in anmodel of microRNA-21-induced pre-B-cell lymphoma","volume":"467","author":"Slack","year":"2010","journal-title":"Nature"},{"key":"28","doi-asserted-by":"crossref","first-page":"23824","DOI":"10.1038\/srep23824","article-title":"Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Pandolfi","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"30","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/pros.22600","article-title":"Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer","volume":"73","author":"Mao","year":"2013","journal-title":"Prostate"},{"key":"31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nrm3287","article-title":"Metabolism: Keeping fit with autophagy","volume":"13","author":"David","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"32","first-page":"102735","article-title":"Role of the Crosstalk between Autophagy and Apoptosis in Cancer","volume":"2013","author":"Sinha","year":"2013","journal-title":"J Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.26374","article-title":"Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma","volume":"131","author":"Yoshimori","year":"2012","journal-title":"Int J Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Sherman","year":"2011","journal-title":"Hepatology"},{"key":"35","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Mills","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.semcancer.2013.05.004","article-title":"Autophagy proteins regulate cell engulfment mechanisms that participate in cancer","volume":"23","author":"Overholtzer","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jhep.2010.10.043","article-title":"Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice","volume":"55","author":"Sun","year":"2011","journal-title":"J Hepatol"},{"key":"38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2014.09.011","article-title":"2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and \u22122","volume":"355","author":"Sun","year":"2014","journal-title":"Cancer Lett"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T14:41:29Z","timestamp":1589294489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":38,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2016,11,8]]}},"alternative-id":["12304","27689326"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12304","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}